GEORGE SIMON

TitleProfessor
InstitutionMD Anderson
DepartmentThoracic Head & Neck Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lawrence MN, Tamen RM, Martinez P, Sable-Hunt A, Addario T, Barbour P, Shaffer T, Hosseini SA, Bertucci C, Lim LP, Hong F, Michael K, Simon GR, Riess JW, Awad MM, Oxnard GR. SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping. JTO Clin Res Rep. 2021 Apr; 2(4):100151. PMID: 34590008.
      Citations:    
    2. Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475. PMID: 33096027.
      Citations: 15     Fields:    Translation:Humans
    3. Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, Simon GR, Blumenschein GR, Papadimitrakopoulou VA, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799. PMID: 33097651.
      Citations: 4     Translation:HumansCTClinical Trials
    4. Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, Lin SH, Heymach JV. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2). PMID: 33051340.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    5. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927. PMID: 32916308.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    6. Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao AS. A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463. PMID: 32608142.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Whisenant MS, Williams LA, Garcia Gonzalez A, Mendoza T, Shi Q, Cleeland C, Zhang J, Heymach J, Simon G. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160. PMID: 32539654.
      Citations:    Translation:Humans
    8. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459. PMID: 32389639.
      Citations: 20     Fields:    Translation:Humans
    9. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536. PMID: 32193228.
      Citations: 3     Fields:    Translation:HumansCells
    10. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257. PMID: 31778797.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    11. Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909. PMID: 31658994.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    12. Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273. PMID: 31605794.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    13. Shi B, Behrens C, Vaghani V, Riquelme EM, Rodriguez-Canales J, Kadara H, Lin H, Lee J, Liu H, Wistuba I, Simon G. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer. Cancer Med. 2019 10; 8(14):6383-6392. PMID: 31456359.
      Citations: 4     Fields:    Translation:HumansCells
    14. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158. PMID: 31445783.
      Citations:    Fields:    
    15. Frederickson AM, Arndorfer S, Zhang I, Lorenzi M, Insinga R, Arunachalam A, Burke TA, Simon GR. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer: a network meta-analysis. Immunotherapy. 2019 04; 11(5):407-428. PMID: 30712477.
      Citations: 15     Fields:    Translation:Humans
    16. Mendoza TR, Kehl KL, Bamidele O, Williams LA, Shi Q, Cleeland CS, Simon G. Assessment of baseline symptom burden in treatment-naïve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447. PMID: 30661202.
      Citations: 11     Fields:    Translation:Humans
    17. Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ. Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer. Cancer Immunol Immunother. 2019 Mar; 68(3):517-527. PMID: 30591959.
      Citations: 9     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    18. Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist. 2019 06; 24(6):772-782. PMID: 30446581.
      Citations: 8     Fields:    Translation:Humans
    19. Somaiah N, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K, Lazar A, Conley AP, Ravi V, Hwu P, Futreal A, Simon G, Meric-Bernstam F, Hong D. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899. PMID: 29731991.
      Citations: 6     Fields:    
    20. Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, Meric-Bernstam F, Subbiah V. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141. PMID: 29748008.
      Citations: 10     Fields:    Translation:Humans
    21. Hwang JP, Lok AS, Fisch MJ, Cantor SB, Barbo A, Lin HY, Foreman JT, Vierling JM, Torres HA, Granwehr BP, Miller E, Eng C, Simon GR, Ahmed S, Ferrajoli A, Romaguera J, Suarez-Almazor ME. Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol. 2018 Apr 01; 36(10):959-967. PMID: 29447061.
      Citations: 6     Fields:    
    22. Hwang JP, Suarez-Almazor ME, Cantor SB, Barbo A, Lin HY, Ahmed S, Chavez-MacGregor M, Donato-Santana C, Eng C, Ferrajoli A, Fisch MJ, McLaughlin P, Simon GR, Rondon G, Shpall EJ, Lok AS. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376. PMID: 28518219.
      Citations: 3     Fields:    Translation:HumansCells
    23. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017 Jan; 3(1):a001115. PMID: 28050598.
      Citations: 38     Fields:    
    24. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol. 2016; 6:239. PMID: 27896216.
      Citations: 16     
    25. Shen C, Kehl KL, Zhao B, Simon GR, Zhou S, Giordano SH. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clin Lung Cancer. 2017 07; 18(4):e233-e241. PMID: 28024927.
      Citations: 10     Fields:    Translation:Humans
    26. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol. 2016; 6:112. PMID: 27200298.
      Citations: 17     
    27. Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res. 2016 Feb 01; 76(3):675-85. PMID: 26676756.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    28. Gray JE, Infante JR, Brail LH, Simon GR, Cooksey JF, Jones SF, Farrington DL, Yeo A, Jackson KA, Chow KH, Zamek-Gliszczynski MJ, Burris HA. A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Invest New Drugs. 2015 Dec; 33(6):1187-96. PMID: 26403509.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    29. Campos-Gomez S, Lara-Guerra H, Routbort MJ, Lu X, Simon GR. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report. Int J Biol Markers. 2015 May 26; 30(2):e254-7. PMID: 25588859.
      Citations: 1     Fields:    Translation:Humans
    30. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693.
      Citations: 43     Fields:    Translation:Humans
    31. Simon GR. nab-Paclitaxel for the treatment of advanced squamous non-small-cell lung cancer: a comprehensive update. Clin Lung Cancer. 2014 Nov; 15(6):391-7. PMID: 25246384.
      Citations: 6     Fields:    Translation:HumansAnimals
    32. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528. PMID: 25594059.
      Citations: 8     
    33. Riquelme E, Suraokar M, Behrens C, Lin HY, Girard L, Nilsson MB, Simon G, Wang J, Coombes KR, Lee JJ, Hong WK, Heymach J, Minna JD, Wistuba II. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61. PMID: 24850841.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    34. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433. PMID: 24722523.
      Citations: 71     Fields:    Translation:HumansAnimalsCells
    35. Aggarwal C, Li L, Borghaei H, Mehra R, Somaiah N, Turaka A, Langer CJ, Simon GR. Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgery. Cancer Control. 2014 Jan; 21(1):57-62. PMID: 24357742.
      Citations: 6     Fields:    Translation:Humans
    36. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer. 2014 Jan; 15(1):21-51. PMID: 24377743.
      Citations: 9     Fields:    Translation:Humans
    37. Behrens C, Solis LM, Lin H, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran CA, Kalhor N, Swisher SG, Simon GR, Stewart DJ, Lee JJ, Wistuba II. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65. PMID: 24097870.
      Citations: 65     Fields:    Translation:Humans
    38. Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct; 36(8):442-50. PMID: 23994887.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    39. Simon GR, Manegold C, Barker SS, Treat JA, Visseren-Grul C, Obasaju C. Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer. Clin Lung Cancer. 2013 Nov; 14(6):601-8. PMID: 23921171.
      Citations: 3     Fields:    Translation:HumansAnimals
    40. Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul 01; 31(19):2404-12. PMID: 23690416.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    41. Creelan BC, Antonia S, Bepler G, Garrett TJ, Simon GR, Soliman HH. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology. 2013 Mar 01; 2(3):e23428. PMID: 23802083.
      Citations: 30     
    42. Somaiah N, Simon NG, Simon GR. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S342-68. PMID: 23160320.
      Citations: 6     Fields:    Translation:Humans
    43. Chakravarty S, Lai WC, Zou Y, Drabkin HA, Gemmill RM, Simon GR, Chin SH, Chen RT. Multiplexed specific label-free detection of NCI-H358 lung cancer cell line lysates with silicon based photonic crystal microcavity biosensors. Biosens Bioelectron. 2013 May 15; 43:50-5. PMID: 23274197.
      Citations: 10     Fields:    Translation:HumansCells
    44. Macpherson IR, Poondru S, Simon GR, Gedrich R, Brock K, Hopkins CA, Stewart K, Stephens A, Evans TR. A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. Eur J Cancer. 2013 Mar; 49(4):782-9. PMID: 23099006.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    45. Aggarwal C, Somaiah N, Simon G. Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther. 2012 Mar; 13(5):247-63. PMID: 22481432.
      Citations: 30     Translation:Humans
    46. West L, Vidwans SJ, Campbell NP, Shrager J, Simon GR, Bueno R, Dennis PA, Otterson GA, Salgia R. A novel classification of lung cancer into molecular subtypes. PLoS One. 2012; 7(2):e31906. PMID: 22363766.
      Citations: 36     Fields:    Translation:HumansCells
    47. Tanner NT, Gomez M, Rainwater C, Nietert PJ, Simon GR, Green MR, Silvestri GA. Physician preferences for management of patients with stage IIIA NSCLC: impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012 Feb; 7(2):365-9. PMID: 22237260.
      Citations: 8     Fields:    Translation:Humans
    48. Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7. PMID: 22176813.
      Citations: 11     Fields:    Translation:Humans
    49. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1758-85. PMID: 22005529.
      Citations: 7     Fields:    Translation:Humans
    50. Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May 01; 118(9):2525-31. PMID: 22028294.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    51. Simon GR. Personalized lung cancer treatment based on molecular determinants. J S C Med Assoc. 2011 Oct; 107(5):183-4. PMID: 22057801.
      Citations:    Fields:    Translation:Humans
    52. Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, André V, Kadam SK, Nasir A, Holzer TR, Meric-Bernstam F, Fishman M, Simon G. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91. PMID: 21831956.
      Citations: 52     Fields:    Translation:HumansCTClinical Trials
    53. Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105. PMID: 21791630.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    54. Simon GR, Ilaria RL, Sovak MA, Williams CC, Haura EB, Cleverly AL, Sykes AK, Wagner MM, de Alwis DP, Slapak CA, Miller MA, Spriggs DR. A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2011 Nov; 68(5):1233-41. PMID: 21431416.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    55. Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2011 Mar; 6(3):553-8. PMID: 21289520.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    56. Simon GR, Silvestri GA. You just can't call it lung cancer anymore. J Thorac Oncol. 2011 Feb; 6(2):239-40. PMID: 21252714.
      Citations: 4     Fields:    Translation:Humans
    57. Stinchcombe TE, Baggstrom MQ, Somaiah N, Simon GR, Govindan R. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010). J Thorac Oncol. 2011 Jan; 6(1):227-32. PMID: 21178721.
      Citations: 2     Fields:    Translation:Humans
    58. Somaiah N, Simon GR. Molecular targeted agents and biologic therapies for non-small cell lung cancer. J Thorac Oncol. 2010 Dec; 5(12 Suppl 6):S434-54. PMID: 21102235.
      Citations: 5     Fields:    Translation:Humans
    59. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801. PMID: 20679538.
      Citations: 224     Fields:    Translation:Humans
    60. Aggarwal C, Somaiah N, Simon GR. Biomarkers with predictive and prognostic function in non-small cell lung cancer: ready for prime time? J Natl Compr Canc Netw. 2010 Jul; 8(7):822-32. PMID: 20679541.
      Citations: 20     Fields:    Translation:Humans
    61. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar 10; 28(8):1387-94. PMID: 20142592.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    62. Simon GR. Treatment of older patients with non-small-cell lung cancer: walking the therapeutic tightrope. J Clin Oncol. 2010 Feb 01; 28(4):523-6. PMID: 20038720.
      Citations:    Fields:    Translation:Humans
    63. Somaiah N, Simon GR. Molecular targeted therapy in non-small cell lung cancer: an overview of available agents. J Thorac Oncol. 2009 Nov; 4(11 Suppl 3):S1046-56. PMID: 19861914.
      Citations: 1     Fields:    Translation:Humans
    64. Goodgame B, Stinchcombe TE, Simon G, Wozniak A, Govindan R. Recent advances in lung cancer: summary of presentations from the 45th annual meeting of the American Society of Clinical Oncology (2009). J Thorac Oncol. 2009 Oct; 4(10):1293-300. PMID: 20197737.
      Citations: 1     Fields:    Translation:Humans
    65. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009 Oct 06; 101(7):1044-50. PMID: 19738609.
      Citations: 64     Fields:    Translation:HumansCellsCTClinical Trials
    66. Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West HJ, Herbst R, Johnson D, Bunn P, Govindan R. Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. J Thorac Oncol. 2009 Jul; 4(7):930-5. PMID: 19550249.
      Citations:    Fields:    Translation:Humans
    67. Simon GR. Individualizing chemotherapy for non-small cell lung cancer (NSCLC) in the adjuvant and advanced setting: current status and future directions. Curr Treat Options Oncol. 2008 Dec; 9(4-6):300-12. PMID: 19266288.
      Citations: 1     Fields:    Translation:Humans
    68. Borghaei H, Mehra R, Simon G. Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Future Oncol. 2009 Feb; 5(1):19-22. PMID: 19243293.
      Citations:    Fields:    
    69. Hoda D, Simon GR, Garrett CR. Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab. Ther Clin Risk Manag. 2008 Dec; 4(6):1221-7. PMID: 19337429.
      Citations: 5     
    70. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1112-8. PMID: 18827606.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    71. Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol. 2008 Jul 20; 26(21):3567-72. PMID: 18640937.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    72. Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May 01; 112(9):2021-9. PMID: 18300255.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    73. Bepler G, Begum M, Simon GR. Molecular analysis-based treatment strategies for non-small cell lung cancer. Cancer Control. 2008 Apr; 15(2):130-9. PMID: 18376380.
      Citations: 9     Fields:    Translation:Humans
    74. Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. J Clin Oncol. 2008 Mar 20; 26(9):1465-71. PMID: 18349397.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    75. Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams C, Simon G, Antonia S, Sullivan DM, Bepler G. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008 Mar 01; 14(5):1464-9. PMID: 18316570.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    76. Simon GR, Begum M, Bepler G. Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer. Future Oncol. 2008 Feb; 4(1):51-9. PMID: 18241000.
      Citations: 9     Fields:    Translation:Humans
    77. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 2007 Nov 18; 257(2):244-51. PMID: 17910902.
      Citations: 39     Fields:    Translation:HumansCells
    78. Homsi J, Simon GR, Garrett CR, Springett G, De Conti R, Chiappori AA, Munster PN, Burton MK, Stromatt S, Allievi C, Angiuli P, Eisenfeld A, Sullivan DM, Daud AI. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res. 2007 Oct 01; 13(19):5855-61. PMID: 17908979.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    79. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132(3 Suppl):324S-339S. PMID: 17873178.
      Citations: 43     Fields:    Translation:Humans
    80. Samson DJ, Seidenfeld J, Simon GR, Turrisi AT, Bonnell C, Ziegler KM, Aronson N. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep; 132(3 Suppl):314S-323S. PMID: 17873177.
      Citations: 14     Fields:    Translation:Humans
    81. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul 01; 25(19):2741-6. PMID: 17602079.
      Citations: 62     Fields:    Translation:HumansCellsCTClinical Trials
    82. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 2007; 39(7-8):1318-28. PMID: 17600754.
      Citations: 26     Fields:    Translation:HumansCells
    83. Münster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007 May 20; 25(15):1979-85. PMID: 17513804.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    84. de Lima Lopes G, Chiappori A, Simon G, Haura E, Sullivan D, Antonia S, Langevin M, Lush R, Rocha-Lima CM. Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas. Cancer. 2007 Apr 01; 109(7):1413-9. PMID: 17326096.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    85. Gray J, Simon G, Bepler G. Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr; 7(4):545-9. PMID: 17428174.
      Citations: 4     Fields:    Translation:Humans
    86. Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Greco FA, Jones SF, Willcut N, Chodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcelpoil R, Mayfield SD, Mauro D, Garrett CR. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007 Feb 01; 13(3):986-93. PMID: 17289894.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    87. Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz S, Cosgriff TM, Pierce K, Xu H, Liau K, Healey D. A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC). Cancer Chemother Pharmacol. 2007 Jun; 60(1):81-9. PMID: 17031646.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    88. Ismail-Khan R, Robinson LA, Williams CC, Garrett CR, Bepler G, Simon GR. Malignant pleural mesothelioma: a comprehensive review. Cancer Control. 2006 Oct; 13(4):255-63. PMID: 17075562.
      Citations: 54     Fields:    Translation:Humans
    89. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10; 24(29):4731-7. PMID: 16966686.
      Citations: 112     Fields:    Translation:HumansCellsCTClinical Trials
    90. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug; 5(8):2130-7. PMID: 16928835.
      Citations: 1     Translation:HumansCTClinical Trials
    91. Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 01; 12(15):4645-51. PMID: 16899614.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    92. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon G, Janssen W, Lee JH, Menander K, Chada S, Gabrilovich DI. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):878-87. PMID: 16467102.
      Citations: 141     Fields:    Translation:HumansCellsCTClinical Trials
    93. Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan 15; 12(2):523-8. PMID: 16428495.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    94. Crane EJ, Simon G. Adjuvant chemotherapy for non-small cell lung cancer. Curr Treat Options Oncol. 2006 Jan; 7(1):51-8. PMID: 16343368.
      Citations: 1     Fields:    Translation:Humans
    95. Chiappori A, Simon G, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology. 2005; 68(4-6):382-90. PMID: 16020967.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    96. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005 Mar; 127(3):978-83. PMID: 15764785.
      Citations: 87     Fields:    Translation:HumansCells
    97. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004 Aug; 126(2):347-51. PMID: 15302716.
      Citations: 53     Fields:    Translation:Humans
    98. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004 May 15; 22(10):1878-85. PMID: 15143080.
      Citations: 73     Fields:    Translation:Humans
    99. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep-Oct; 10(5):388-95. PMID: 14581894.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    100. Simon GR, Bunn PA. Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments. Cancer Invest. 2003; 21(1):87-104. PMID: 12643013.
      Citations: 4     Fields:    Translation:HumansCells
    101. Simon GR, Wagner H. Small cell lung cancer. Chest. 2003 Jan; 123(1 Suppl):259S-271S. PMID: 12527584.
      Citations: 44     Fields:    Translation:Humans
    102. Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am. 2001 Feb; 11(1):165-88, ix. PMID: 11253596.
      Citations: 5     Fields:    Translation:Humans
    103. Banda NK, Simon GR, Sipple JD, Terrell KL, Archer P, Shpall EJ, Akkina RK, Myers AM, Harrison GS. Depletion of CD34+ CD4+ cells in bone marrow from HIV-1-infected individuals. Biol Blood Marrow Transplant. 1999; 5(3):162-72. PMID: 10392962.
      Citations: 9     Fields:    Translation:HumansCells
    104. Melhoria da sobrevida em não fumadores versus fumadores com adenocarcinoma primitivo do pulmão. Revista Portuguesa de Pneumologia. 10:510-512.
    105. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Frontiers in Oncology. 6.
    106. Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. OncoImmunology. 2.
    107. Docetaxel Plus Cisplatin. American Journal of Cancer. 2:357-358.
    108. Silicon photonic crystal microcavity biosensors for label free highly sensitive and specific lung cancer detection. 443-444.
    109. Novel agents in development and future directions. 215-235.
    110. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 1:522-528.
    111. Blood-based early detection of malignant mesothelioma. Journal of Clinical Oncology. 27:160-162.
    112. Recent advances in immunotherapy in metastatic NSCLC. Frontiers in Oncology. 6.
    113. Non-Small Cell Lung Cancers (NSCLC) with Mutations in BRAF. 557-563.
    114. Utilization Patterns and Trends in Epidermal Growth Factor Receptor (EGFR) Mutation Testing Among Patients With Newly Diagnosed Metastatic Lung Cancer. Clinical Lung Cancer.
    115. Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations. Cancer Research. 76:675-685.
    SIMON's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (338)
    Explore
    _
    Co-Authors (97)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _